Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Creative Medical Technology Holdings, Inc.

NASDAQ: CELZ · Life Sciences · 3 alerts · CIK 1187953

Share price
$0.5201Close, Nov 16
Market cap
$3.95M
Shares outstanding
7.6MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Creative Medical Technology Holdings, Inc. filings on SEC EDGAR ↗

4:07 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Creative Medical Technology Holdings Nasdaq/NYSE Compliance Notice

Creative Medical Technology Holdings received a deficiency notice from Nasdaq on November 10, 2026, for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. The company has until May 10, 2027, to regain compliance by having its stock close at or above $1.00 for at least ten consecutive business days. The notice has no immediate impact on the listing of the company's common stock (CELZ).

Counterparty
The Nasdaq Stock Market
Term
180 days
4:46 PM ET 10-Q
Financial Results

Creative Medical Technology Holdings Q3 2026 Results: Net Loss of $2.67M, Loss Widens

Creative Medical Technology Holdings reported a net loss of $5.59 million for the nine months ended September 30, 2026, driven by increased research and development and SG&A expenses. The company remains in a pre-revenue stage for the current period, though it successfully raised approximately $4.06 million through warrant exercises and stock sales to support its regenerative therapy pipeline.

Key figure
Net loss $2.67M
5:01 PM ET 8-K
M&A Deal

Creative Medical Technology Holdings M&A Deal with BioDefense, Inc.

Creative Medical Technology Holdings acquired 4,000,000 shares of BioDefense, Inc. from Creative Acquisition Corp. for $200,000 in cash and 1,000,000 shares of its own common stock. Following the transaction, the company owns 80% of BioDefense, Inc., making it a majority-owned subsidiary.

Counterparty
BioDefense, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.